Botulinum Neurotoxin for Children With Cerebral Palsy: a Delicate Balance Between Clinical Benefits and Muscular Harm
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
A cross-sectional design study will be carried out to explore the morphological muscle properties and alterations in muscle composition on a macroscopic level in children with spastic cerebral palsy (CP). Muscle composition will be assessed using quantitative Magnetic Resonance Imaging (qMRI) and shear wave elastography (SWE), while macroscopic muscle size properties will be evaluated through 'Three-dimensional freehand ultrasound (3DfUS).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 16
Healthy Volunteers: t
View:
• Children (boys/girls) with congenital brain lesion, confirmed with neuro-imaging such as MRI
• At high-risk for CP or diagnosed spastic type of CP
• (Suspected) Gross Motor Function Classification Scale (GMFCS) Level I-III
• Uni or bilateral involvement
• Aged between 2-16 years
⁃ • Aged between 2-16 years
Locations
Other Locations
Belgium
UZ Leuven
RECRUITING
Leuven
Contact Information
Primary
Charlotte Lambrechts
charlotte.lambrechts@kuleuven.be
+32489421264
Backup
Julie Stegen
julie.stegen@kuleuven.be
+32477273954
Time Frame
Start Date: 2025-02-03
Estimated Completion Date: 2028-12
Participants
Target number of participants: 51
Treatments
Children with spastic cerebral palsy
Children between 2 years and 16 years old
Typically developing children
Children between 2 years and 16 years old
Related Therapeutic Areas
Sponsors
Leads: Universitaire Ziekenhuizen KU Leuven